Abstract 448P
Background
Chemotherapy efficacy depends on relative dose intensity (RDI) and an RDI <85% is associated with unfavourable overall survival. Clinicopathological characteristics have been observed as risk factors of reduced RDI. The pro-inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), which also serve as biomarkers of aging, have been reported to associate with RDI. We aimed to determine whether these parameters have influence on RDI in the local breast cancer (BC) patients.
Methods
This cross-sectional study recruited 172 women with stage I-IV BC receiving first-line chemotherapy between July 2018-March 2022. Sociodemographic, clinicopathological, and treatment data and peripheral blood samples were collected prior to chemotherapy. IL-6 and CRP levels were analyzed using quantitative ELISA. Dose reductions and delays were captured and utilized to calculate the patient’s RDI. Multivariable logistic regression analysis was performed to determine the association between pre-chemotherapy parameters and RDI <85%.
Results
Mean age was 52 years (range 32-78). The average RDI for all patients was 93% and an RDI <85% occurred in 23 (13.4%) patients. Mean IL-6 level was 1.12 pg/ml (range 0.0–27.7) and mean CRP was 10.82 μg/ml (range 0.0–151.7). Factors associated with reduced RDI were diabetes mellitus comorbidity (OR 5.13, 95% CI 1.38–19.03; p =0.015), triple-negative tumours (OR 4.17, 95% CI 1.09–15.89; p =0.037), palliative treatment setting (OR 3.75, 95% CI 1.12–12.62, p =0.032), and IL-6 serum level >0.485 pg/ml (OR 3.46, 95% CI 1.05–11.37; p =0.041).
Conclusions
The presence of diabetes mellitus comorbidity, triple-negative tumours, palliative treatment intention, and IL-6 serum level >0.485 pg/ml are associated with reduced RDI. Further investigation is warranted to confirm the association between biomarker of aging and chemotherapy delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, The Ministry of Education, Culture, Research, and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract